ENNOVA Health

Ennova Bio (also known as Ennova Health) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule and biologic therapies for oncology and autoimmune diseases. The company leverages its expertise in structure-based drug design and medicinal chemistry to target high-value pathways such as TYK2, HPK1, and the RAS/MAPK signaling axis. Its lead candidate, EB-002, is a highly selective TYK2 inhibitor currently being evaluated for the treatment of psoriasis and other inflammatory conditions. Ennova Bio maintains operations in both China and the United States, aiming to address significant unmet medical needs globally.